Filtered By:
Cancer: HNSCC
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CONCLUSIONS: MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.PMID:36455147 | DOI:10.1158/1078-0432.CCR-22-1987
Source: Clinical Cancer Research - December 1, 2022 Category: Cancer & Oncology Authors: Charu Aggarwal Nabil F Saba Alain Algazi Ammar Sukari Tanguy Y Seiwert Missak Haigentz Mercedes Porosnicu Marcelo Bonomi Jean Boyer Mark T Esser Lily I Cheng Sonia Agrawal Emily C Jennings Nicholas M Durham Karl Fraser Delphine Lissa Maozhen Gong Natalia Source Type: research
Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer
Cancer J. 2022 Sep-Oct 01;28(5):407-415. doi: 10.1097/PPO.0000000000000621.ABSTRACTDespite the availability of prophylactic human papillomavirus (HPV) vaccines, there is a growing incidence of HPV-associated head and neck squamous cell carcinomas (HPV-HNSCC) worldwide. The viral etiology of HPV-HNSCC provides an opportunity to develop personalized immune-based therapies, which target the unique viral- or tumor-specific proteins. Novel HPV-targeted immunotherapeutic approaches in clinical development are reviewed. Early results from these trials highlight new opportunities and potential challenges ahead. Immunotherapies for...
Source: Cancer Journal - September 27, 2022 Category: Cancer & Oncology Authors: Jean S Campbell Sara I Pai Source Type: research
